ChemComm

Chemical probing of thiotetronate bio-assembly†

Judith Havemann,[a] Marie E. Yurkovich,[b] Robert Jenkins,[a] Sophia Harringer,[a] Weixin Tao,[c] Shishi Wen,[c] Yuhui Sun,[c] Peter F. Leadlay[b] and Manuela Tosin*[a]

Chemical 'chain termination' probes were utilised for the investigation of thiotetronate antibiotic biosynthesis in the filamentous bacteria *Lentzea* sp. and *Streptomyces thiolactonus* NRRL 15439. The use of these tools led to the capture of biosynthetic intermediates involved in the thiotetronate polyketide backbone assembly, providing first insights into substrate specificity and *in vivo* intermediate processing by unusual iterative synthases.

Polyketide natural products constitute a prominent class of secondary metabolites that interact with a wide range of intracellular targets associated with diseases.[1] The presence of heterocyclic moieties in polyketides, such as pyran and furan rings in ionophore antibiotics, is common and often decisive for the physical properties and biological activity of the compound.[2] Although sulphur-ring based structures are relatively common in peptides of both ribosomal and nonribosomal origin,[3] polyketides bearing sulphur-containing rings are rare. They include potent antitumor agents such as leinamycin[4] and the family of thiotetronate antibiotics (Fig. 1).[5–10] Thiotetronates are characterised by thiolactone moieties functionalised with different substituents at positions 3, 5 and 7, a tetronate moiety spanning carbons 2–4 and a stereogenic centre at carbon 5. The best-known thiotetronate is thiolactomycin (1, TLM): originally isolated from a soil *Nocardia* strain (ATCC 31319,[7] recently reclassified as *Lentzea* sp.), 1 is a reversible inhibitor of the β-ketoacyl-acyl carrier protein synthase (KAS) enzymes of the bacterial type II (dissociated) fatty acid synthase.[11] TLM constitutes a promising lead structure for the

[a] *Department of Chemistry, University of Warwick, Library Road, CV4 7AL, UK. E-mail: M.Tosin@warwick.ac.uk; Tel: +44(0) 2476572878*

[b] *Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK*

[c] *Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (Wuhan University), Ministry of Education, Wuhan University School of Pharmaceutical Sciences, Wuhan 430071, People's Republic of China*

† Electronic supplementary information (ESI) available: General methods for the synthesis of chemical probes, *Lentzea* sp. genetic manipulation and LC-HRMS analysis of the biosynthetic intermediates isolated from *Lentzea* sp. and *S. thiolactonus* strains. See DOI: 10.1039/c6cc09933e

Fig. 1 (A) Structure of thiotetronate polyketides thiolactomycin (1) and Tü 3010 (2) and (B) overview of their recently elucidated gene clusters from *Lentzea* sp. and *S. thiolactonus* NRRL 15439, respectively.[5,6] Legend: J = tRNA-specific thiouridylase; K = *N*-acetylmuramoyl-L-alanine amidase; S = NifS-like cysteine desulfurase; E = asparagine synthase; G = ferredoxin; D₁ and D₂ = cytochrome P450s; F₃ = 3-oxoacyl-ACP-synthase III (FabH); T = thioesterase; H = crotonyl-CoA reductase; I = 3-hydroxybutyryl-CoA dehydrogenase; R = LuxR family transcriptional regulator; F, F₁ and F₂ = 3-oxoacyl-ACP-synthases (FabB/F); A = PKS; B = PKS/NRPS; C = NRPS.

development of novel anti-tuberculosis, anti-malarial and anti-trypanosomal agents.[12–14] The closely structurally related Tü 3010 (2) has been reported to be the most potent antibacterial tetronate to date, capable of targeting FabH/FabF in *Staphylococcus aureus* at lower doses in comparison to TLM and other known FabH/FabF inhibitors.[15] Only very recently these medicinally promising molecules were unequivocally established to be of polyketide origin.[5–6,16] Comparative genomics-based approaches to orphan cluster identification led to the uncovering of putative polyketide synthase (PKS)-nonribosomal peptide synthetase (NRPS) enzymes (A–C, Fig. 1B) responsible for thiotetronate production in both soil and marine bacteria, in association with tailoring enzymes (*e.g.* P450 oxidases, D), cysteine desulfurases (J) and (thiouridylase-like) sulfur transferases (S) proposed to provide the sulfur atom for thiotetronate ring formation.[5,6] Indeed, genes A, B, D₁, D₂, J and S are essential for thiotetronate formation, as proved by *in vivo* knock-out and complementation studies.[5] Genes A and B encode for an acetyl-loading PKS module and a hybrid PKS-NRPS, respectively. For the thiolactomycin biosynthetic gene cluster tlm, the B protein comprises ketosynthase (KS), acyltransferase (AT),

dehydratase (DH), ketoreductase (KR), acyl carrier protein (ACP), cyclisation (Cy), adenylation (A), peptidyl carrier protein (PCP) and thioesterase (TE) domains (Fig. 3). A number of biosynthetic hypotheses have been so far proposed regarding the origins of TLM and other thiotetronates on the basis of precursor feeding studies[16] and gene/protein bioinformatics.[5,6] However, the actual molecular mechanisms of product assembly remain undetermined and are the object of intense scrutiny with a view to thiotetronate structural diversification *via* enzyme engineering.

Polyketide biosynthesis proceeds *via* decarboxylative Claisen condensation of malonate units anchored to acyl carrier proteins (ACPs) with acyl moieties bound to ketosynthase (KS) domains (Fig. 3, path A): the resulting polyketide chain is subjected to variable ketoreduction, dehydration and enoyl reduction after chain extension, before being released from PKSs (*e.g. via* thioester hydrolysis) and/or post-PKS tailoring (*e.g. via* methyltransferases, glycosyltransferases,...).[17,18] A detailed elucidation of the polyketide assembly is crucial for knowledge-based enzyme and cell engineering aiming at novel polyketide production.[19–21] Advances in molecular biology, synthetic chemistry and analytical techniques have greatly aided the probing of PKS pathways *in vitro* and *in vivo*.[5,6,22–25] Nonetheless, several challenges remain concerning the elucidation of timing and mechanisms related to the polyketide assembly, mostly related to the inaccessibility of biosynthetic intermediates covalently linked to PKSs throughout the product assembly.

We have developed a general strategy for probing polyketide biocatalysis based on the use of synthetic 'chain termination' probes: these are nonhydrolysable small-molecule mimics of malonate extender units recruited in polyketide formation that competitively interfere in the decarboxylative Claisen condensation to capture and off-load prematurely truncated biosynthetic intermediates (Fig. 3, path B).[26–32] These chemical tools have proved successful for the identification and characterisation of intermediate species from modular[26–29,32] and iterative[30,31] PKSs, *in vitro* and *in vivo*, allowing the gathering of otherwise inaccessible information on the timing and the mechanism of single catalytic events,[28,30] and also unveiling novel chemoenzymatic opportunities for the generation of unnatural polyketide derivatives.[29] In order to shed light on the nature of the biosynthetic intermediates involved in the thiotetronate assembly and their *in vivo* processing, we have utilised a range of chain termination probes available in our labs. We initially employed the N-(d_3) acetyl methyl ester probes **3a–b**, which hydrolyse *in vivo* to the corresponding 'active' carboxylate probes **7a–b** (Fig. 2), in microbial fermentations of the wild type thiolactomycin producing *Lentzea* sp. at variable probe concentrations. In organic extracts of cultures we observed diminished production of thiolactomycin with increasing concentrations of **3a–b**, strongly suggesting that the probes were interfering in the thiotetronate assembly. However, only a handful of putative captured intermediates were detected from these substrates (Table S2, ESI†). We therefore turned to second-generation probes featuring N-decanoyl chains, which have recently proved to be more efficient tools in capturing polyketide intermediates *in vivo* due to their enhanced bioavailability and


Fig. 2 Overview of chemical probes utilised in this study.

ease of intermediate isolation.[32] In addition to substrates **4–5** previously reported,[29–32] we also synthesised and utilised the pseudo-methylmalonyl ester **6** (Scheme S1, ESI†), in order to probe the extender unit substrate specificity of the putative iterative PKSs. In parallel to wild-type strains, mutant strains carrying specific deletions in both *Lentzea* sp. (ΔtlmA,[5] ΔtlmD1[5] and Δcy) and *S. thiolactonus* NRRL 15439 (ΔstuB and ΔJΔKΔS),[5] as well as *Streptomyces avermitilis* heterologously expressing the Tü 3010 cluster,[5] were utilised in control experiments.

An overview of the outcome of feeding experiments of *Lentzea* sp. and *S. thiolactonus* strains with compounds **7–10** is given in Fig. 3 and detailed in Tables S2–S5 (ESI†). Although malonate and methylmalonate-mimic probes **8** and **10** preferentially intercepted early stage condensation intermediates, the use of the fluoromalonate-based probe **9** in wild-type *Lentzea* sp. fermentations captured diketides and triketides presenting various degrees of reduction, as well as putative tetraketides (Table S2, ESI†). These species, directly mirroring the nature of ACP-bound species,[5] were characterised by high resolution mass spectrometry tandem experiments, with diagnostic peaks corresponding to the loss of the N-decanoyl moiety and loss of ammonia, and/or cyclic imine formation[29–32] (Fig. 3). Although diketide species may be potentially captured from the fatty acid biosynthetic pathway (Table S3, ESI†), the observed triketides and tetraketides were associated exclusively with TLM formation *in vivo*. In addition to purely polyketide species, a putative S- and O- containing tetraketide species was also captured from *Lentzea* sp. *via* **9** (Fig. 3C). A parallel investigation of *S. thiolactonus* wild-type, deletion mutant strains and *S. avermitilis* heterologously expressing the Tü 3010 cluster[5] with methyl ester substrates **4–5** led to the capture of similar putative intermediates, albeit with lower efficiency (Tables S4 and S5, ESI†).

These results taken together constitute the first direct evidence of polyketide chain building and processing involved in thiotetronate bio-assembly. By utilising a variety of chemical probes as pseudo-malonate substrates, preliminary information on substrate specificity and the kinetics of polyketide assembly has been obtained. The pseudo-fluoromalonate **9**, generated from *in vivo* hydrolysis of the corresponding methyl ester **5**, proved to be the most efficient tool in capturing almost every intermediate involved in the polyketide TLM assembly. Compared to the malonate and methylmalonate inspired-substrates **4** and **6**, we observed enhanced *in vivo* ester hydrolysis followed by decarboxylation for **5** (Fig. S7, S10 and S20, ESI†): this is possibly due to the electron-withdrawing effect of fluorine at the α-ester carbonyl position, or to the increased probe bioavailability, or to a likely combination of both. On the other

Fig. 3 Overview of (A) polyketide assembly and (B) intermediate capture *via* chemical probes during thiolactomycin (**1**) assembly in *Lentzea* sp. (C) Micro LC-HRMS analyses (LTQ-Orbitrap Fusion) of the organic extracts of *Lentzea* sp. grown in the presence of **5** show the presence of putative tetraketide species captured from the thiolactomycin assembly. Analogous species were captured from cultures of *S. thiolactonus* strains (Table S4 and Fig. S26, S27, ESI†). The stereochemistry of all the captured species remains undetermined. KS = ketosynthase; AT = acyltransferase; DH = dehydratase; KR = ketoreductase; ACP = acyl carrier protein; Cy = (hetero)cyclisation domain; A = adenylation domain; PCP = peptidyl carrier protein; and TE = thioesterase.

hand, **9** did not prove equally efficient in sampling the polyketide chain assembly for Tü 3010, suggesting a much stricter substrate specificity for StuB. By analysing the relative amounts of all the characterised species from *Lentzea* sp., it appears that, in general, early stage substrate processing is relatively slow, as previously observed for other partially reducing iterative type I synthases (iPKSs),[30,31] and that the presence of TlmD1, the TlmB Cy domain and J, K, S proteins is essential for polyketide chain growth and processing beyond the triketide stage. Most type I iPKSs utilise malonate extender units, and methyl groups are introduced into their polyketide products by integral SAM-dependent methyltransferases.[33,34] In this respect, TlmB and StuB display unusual substrate specificity in utilising methylmalonate and ethylmalonate extender units, dictated by their respective AT domains. We have shown here that these unusual iPKSs can also process pseudomalonate, methylmalonate and fluoromalonate substrates at different stages and to various extents. These findings have been corroborated by parallel *in vitro* investigations with recombinant TlmB in our laboratories.[35] We have recently proposed a mechanism for sulphur insertion following the formation of the PKS-bound tetraketide, involving the nonribosomal peptide synthase (NRPS) functionalities encoded in the C-terminal part of TlmB: tetraketide epoxidation (catalysed by TlmD1/StuD1) may precede the formation of a tetraketide–thiirane intermediate from PCP-bound cysteine desulfuration (Tlm/Stu J and S catalysed), followed by heterocyclisation and product release.[5] It is tempting to speculate that the putative S- and O- containing tetraketide species characterised from *Lentzea* sp. and *S. thiolactonus* wild-type strains may be related to this pathway. Further work will be required to establish the true nature of S-containing intermediates leading to thiotetronate formation. Nevertheless, the deconvolution of the steps of chain assembly reported here has set the stage for the investigation of these post-PKS events.

In summary, we have utilised chemical probes to gather the first information on the intermediates in polyketide assembly for thiotetronate formation *in vivo*. This represents an important step towards the full elucidation of thiotetronate assembly and the development of synthetic biology-based routes for novel thiotetronate production.

Notes and references

1 E. Larsen, M. R. Wilson and R. E. Taylor, *Nat. Prod. Rep.*, 2015, **32**, 1183–1206.
2 F. Hemmerling and F. Hahn, *Beilstein J. Org. Chem.*, 2016, **12**, 1512–1550.
3 A. W. Truman, *Beilstein J. Org. Chem.*, 2016, **12**, 1250–1268.
4 M. Ma, J. Lohman, T. Liu and B. Shen, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 10359–10364.
5 W. Tao, M. E. Yurkovich, S. Wen, K. B. Lebe, M. Samborskyy, Y. Liu, A. Yang, Y. Liu, Y. Ju, Z. Deng, M. Tosin, Y. Sun and P. F. Leadlay, *Chem. Sci.*, 2016, **7**, 376–385.
6 X. Tang, J. Li, N. Millán-Aguiñaga, J. J. Zhang, E. C. O'Neill, J. A. Ugalde, P. R. Jensen, S. M. Mantovani and B. S. Moore, *ACS Chem. Biol.*, 2015, **10**, 2841–2849.
7 H. Oishi, T. Noto, H. Sasaki, K. Suzuki, T. Hayashi, H. Okazaki, K. Ando and M. Sawada, *J. Antibiot.*, 1982, **35**, 391–395.
8 S. Omura, Y. Iwai, A. Nakagawa, R. Iwata, Y. Takahashi, H. Shimizu and H. Tanaka, *J. Antibiot.*, 1983, **36**, 109–114.
9 C. Rapp, G. Jung, C. Isselhorst-Scharr and H. Zähnner, *Eur. J. Org. Chem.*, 1988, 1043–1047.
10 T. Sato, K. Suzuki, S. Kadota and M. Iwanami, *J. Antibiot.*, 1989, **42**, 890–896.
11 C. A. Machutta, G. R. Bommineni, S. R. Luckner, K. Kapilashrami, B. Ruzsicska, C. Simmerling, C. Kisker and P. J. Tonge, *J. Biol. Chem.*, 2010, **285**, 6161–6169.
12 L. Kremer, J. D. Douglas, A. R. Baulard, C. Morehouse, M. R. Guy, D. Alland, L. G. Dover, J. H. Lakey, W. R. Jacobs Jr, P. J. Brennan, D. E. Minnikin and G. S. Besra, *J. Biol. Chem.*, 2000, **275**, 16857–16864.
13 S. M. Jones, J. E. Urch, M. Kaiser, R. Brun, J. L. Harwood, C. Berry and I. H. Gilbert, *J. Med. Chem.*, 2005, **48**, 5932–5941.
14 G. R. Bommineni, K. Kapilashrami, J. E. Cummings, Y. Lu, S. E. Knudson, C. Gu, S. G. Walker, R. A. Slayden and P. J. Tonge, *J. Med. Chem.*, 2016, **59**, 5377–5390.

15 K. Young, H. Jayasuriya, J. G. Ondeyka, K. Herath, C. Zhang, S. Kodali, A. Galgoci, R. Painter, V. Brown-Driver, R. Yamamoto, L. L. Silver, Y. Zheng, J. I. Ventura, J. Sigmund, S. Ha, A. Basilio, F. Vicente, J. R. Tormo, F. Pelaez, P. Youngman, D. Cully, J. F. Barrett, D. Schmatz, S. B. Singh and J. Wang, *Antimicrob. Agents Chemother.*, 2006, **50**, 519–526.

16 M. S. Brown, K. Akopiants, D. M. Resceck, H. A. I. McArthur, E. McCormick and K. A. Reynolds, *J. Am. Chem. Soc.*, 2003, **125**, 10166–10167.

17 K. J. Weissman, *Methods Enzymol.*, 2009, **459**, 3–16.

18 C. Hertweck, *Angew. Chem., Int. Ed.*, 2009, **48**, 4618–4716.

19 C. Hertweck, *Trends Biochem. Sci.*, 2015, **40**, 189–240.

20 E. Kim, B. S. Moore and Y. J. Yon, *Nat. Chem. Biol.*, 2015, **11**, 649–659.

21 R. Breitling and E. Takano, *Curr. Opin. Biotechnol.*, 2015, **35**, 46–51.

22 E. S. Sattely, M. A. Fischbach and C. T. Walsh, *Nat. Prod. Rep.*, 2008, **25**, 757–793.

23 S. B. Bumpus and N. L. Kelleher, *Curr. Opin. Chem. Biol.*, 2008, **12**, 475–482.

24 E. Esquenazi, Y.-L. Yang, J. Watrous, W. H. Gerwick and P. C. Dorrestein, *Nat. Prod. Rep.*, 2009, **26**, 1521–1534.

25 S. Nadmid, A. Plaza, R. Garcia and R. Müller, *J. Nat. Prod.*, 2015, **78**, 2023–2028.

26 M. Tosin, L. Betancor, E. Stephens, W. M. A. Li, J. B. Spencer and P. F. Leadlay, *ChemBioChem*, 2010, **11**, 539–546.

27 M. Tosin, Y. Demydchuk, J. S. Parascandolo, C. Blasco-Per, F. J. Leeper and P. F. Leadlay, *Chem. Commun.*, 2011, **47**, 3460–3462.

28 M. Tosin, L. Smith and P. F. Leadlay, *Angew. Chem., Int. Ed.*, 2011, **50**, 11930–11933.

29 E. Riva, I. Wilkening, S. Gazzola, W. M. A. Li, L. Smith, P. F. Leadlay and M. Tosin, *Angew. Chem., Int. Ed.*, 2014, **53**, 11944–11949.

30 H. Kage, E. Riva, J. S. Parascandolo, M. F. Kreutzer, M. Tosin and M. Nett, *Org. Biomol. Chem.*, 2015, **13**, 11414–11417.

31 J. S. Parascandolo, J. Havemann, H. K. Potter, F. Huang, E. Riva, J. Connolly, I. Wilkening, L. Song, P. F. L. Leadlay and M. Tosin, *Angew. Chem., Int. Ed.*, 2016, **55**, 3463–3467.

32 I. Wilkening, S. Gazzola, E. Riva, J. S. Parascandolo, L. Song and M. Tosin, *Chem. Commun.*, 2016, **52**, 10392–10395.

33 R. J. Cox, *Org. Biomol. Chem.*, 2007, **5**, 2010–2026.

34 B. Bonsch, V. Belt, C. Bartel, N. Duensing, M. Koziol, C. M. Lazarus, A. M. Bailey, T. J. Simpson and R. J. Cox, *Chem. Commun.*, 2016, **52**, 6777–6780.

35 M. E. Yurkovich, R. Jenkins, Y. Sun, M. Tosin and P. F. Leadlay, *Chem. Commun.*, 2017, DOI: 10.1039/c6cc09934c.